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Heparan sulfate (HS) is a polysaccharide involved in essential
physiological functions from regulating cell growth to blood co-
agulation. HS biosynthesis involves multiple specialized sulfotrans-
ferases such as 2-O-sulfotransferase (2OST) that transfers the sulfo
group to the 2-OH position of iduronic acid (IdoA) or glucuronic
acid (GlcA) within HS. Here, we report the homotrimeric crystal
structure of 2OST from chicken, in complex with 3-phosphoad-
enosine 5-phosphate. Structural based mutational analysis has
identified amino acid residues that are responsible for substrate
specificity. The mutant R189A only transferred sulfates to GlcA
moieties within the polysaccharide whereas mutants Y94A and
H106A preferentially transferred sulfates to IdoA units. Our results
demonstrate the feasibility for manipulating the substrate speci-
ficity of 2OST to synthesize HS with unique sulfation patterns. This
work will aid the development of an enzymatic approach to
synthesize heparin-based therapeutics.
crystal structure  heparin  protein engineering 
maltose-binding protein chimera  trimeric proteins
Heparan sulfate (HS) is a highly sulfated linear polysaccharideubiquitously present on the cell surface and in the extracellular
matrix. HS participates in a wide range of physiological and
pathophysiological functions, including embryonic development,
inflammatory response, blood coagulation, and assisting viral/
bacterial infections (1). Heparin, a special form of HS, is a com-
monly used anticoagulant drug. The sulfation pattern of the HS
polysaccharide governs its functional selectivity (2). Understanding
the structure–function relationship of HS may allow us to manip-
ulate HS biosynthesis to design HS/heparin with improved antico-
agulant efficacy and exploit heparin or heparin-like molecules for
the development of anticancer and antiviral drugs (3). However,
obtaining HS oligosaccharides or polysaccharides with defined
structures remains a challenge. Despite many examples of success
with chemical synthesis of short-HS fragments, the synthesis of
molecules larger than hexasaccharides is extremely difficult. Using
HS biosynthetic enzymes to prepare biologically active polysaccha-
rides and oligosaccharides has offered a promising alternative
approach (4–7).
The biosynthesis of HS involves a series of specialized en-
zymes, including glycosyl transferases, an epimerase, and various
sulfotransferases [supporting information (SI) Fig. S1]. 2-O-
sulfotransferase (2OST) transfers a sulfo group to the 2-OH
position of iduronic acid (IdoA) or GlcA within the HS chain to
form IdoA2S and GlcA2S respectively (Fig. 1) (8). The functions
of 2-O-sulfated iduronic acid (IdoA2S) in HS have been dem-
onstrated by in vitro and in vivo studies. Unlike IdoA2S, GlcA2S
is much less abundant in the HS isolated from natural sources,
and thus the function of GlcA2S is unknown. The IdoA2S unit
is necessary for binding to numerous fibroblast growth factors
and is crucial for triggering fibroblast growth factor-mediated
signal transduction pathways (9). Only one isoform of 2OST is
present in most vertebrate genomes, and the sequence is highly
conserved across species. Human 2OST shares 97% sequence
identity with the mouse ortholog and 92% identity with the chicken.
The high degree of sequence identity suggests a central physiolog-
ical role in these organisms. The 2OST-knockout mice demonstrate
renal agenesis and die in the neonatal period, and they show
retardation of eye development and skeletal overmineralization
(10). In Caenorhabditis elegans, 2OST has been determined to be
essential for axon migration/guidance and nervous system devel-
opment (11, 12). Dependence on 2-O-sulfation is notably less
critical in Drosophila fibroblast growth factor signaling. It was
suggested that the 2OST/ mutant synthesizes HS with a higher
level of 6-O-sulfation, which may compensate for the reduced
2-O-sulfation in Drosophila (13). Here, we report the crystal struc-
ture of chicken 2OST as a maltose-binding protein (MBP) fusion
protein in complex with 3-phosphoadenosine 5-phosphate (PAP).
Our results provide structural and biochemical information for
delineating the mechanism of action of 2OST and evidence for
altering the substrate specificity of 2OST for the synthesis of HS
with unique biological functions.
Results and Discussion
Comparison with Other Sulfotransferases. A crystal structure of
MBP and the catalytic domain of chicken 2OST (D69–N356) was
solved at the resolution of 2.65 Å (Fig. S2 and Table S1). The 2OST
catalytic domain comprises a conical sulfotransferase / motif that
contains the PAPS-binding loop (Fig. 2A and Fig. S2 b and c).
Despite their global similarities, the crystal structure of 2OST has
distinct differences from other HS sulfotransferases, including
N-sulfotransferase domain of N-deacetylase/N-sulfotransferase-1
(NST) and the 3OST isoforms 1, 3, and 5 for which crystal
structures exist (14–17). Sequence alignments of 2OST to NST and
3OST isoforms only show 12–13% sequence identity compared
with 40–50% among the 3OST isoforms and 28% between NST
and the 3-O-sulfotransferase (3OST) isoforms. The degree of
sequence similarity is consistent with structural comparisons be-
cause NST and 3OST-3 share 234 structurally equivalent Cs with
a rmsd of 1.3 Å, whereas structural comparisons of 2OST with
3OST-3 reveal only 103 structurally equivalent residues with a rmsd
of 2.1 Å. Noticeably absent in 2OST vs. NST and the 3OSTs is an
exterior 3-stranded antiparallel -sheet containing a disulfide bond
and a small loop off the last strand of the central parallel -sheet
where the proposed catalytic glutamic acid base (Glu-184 in
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3OST-3) resides. However, the crystal structure of 2OST exhibits a
unique elongated C-terminal helix followed by a 20-aa tail extend-
ing away from the catalytic domain (Fig. S2 b and c).
HS sulfotransferases are type II transmembrane Golgi-associated
enzymes. Cytosolic sulfotransferases differ from their Golgi-
associated counterparts in that they have a buried hydrophobic
binding pocket for the acceptor substrate, such as a hydrophobic
steroid (18). A structural comparison of 2OST with the cytosolic
enzyme, estrogen sulfotransferase (EST), shows a rmsd of 2.0 Å for
107 structurally equivalent cs but with a slightly higher sequence
identity (16.5%) (19). Interestingly, 7 of the 45 sequence con-
served residues come from the long -helix (V182–L188) equiva-
lent to helix 6 in EST, that runs across the top of both the donor and
acceptor substrate-binding pockets (Fig. 2A). In addition, like
2OST, cytosolic sulfotransferases lack a catalytic glutamate. In-
stead, the cytosolic enzymes use a histidine at the end of the 4th
strand of their central -sheet (19). A structurally equivalent
histidine (His-142) is present in 2OST (Fig. 2 A and B). Xu et al. (20)
had identified this histidine as a potential catalytic residue based on
comparisons with the cytosolic enzymes by using sophisticated
sequence alignments and mutational analysis. In the 2OST struc-
ture, His-142 has 2 apparent conformations. One conformation
positions the side chain away from the substrate binding cleft
(conformation A). The other conformation (conformation B)
superimposes very well with His-108 of EST, positioning the side
chain in the active-site cleft for a possible role in catalysis (Fig. 2A).
Trimeric Complex. The most distinct structural difference between
2OST and the other HS sulfotransferases is that 2OST appears to
function as a trimer. In the crystal structure of MBP-2OST, a 3-fold
crystallographic axis runs through the middle of the trimer (Fig. 3
A and B). This arrangement buries 24% of the surface area of any
1 molecule. Supporting this quaternary structure, the fusion protein
appears to behave as a trimer in solution as determined by gel
filtration chromatography (Fig. S3). The molecular mass of mono-
meric MBP-2OST is 70 kDa. Using a standard curve generated
Fig. 1. Reactions catalyzed by 2OST. 2OST sulfates either the GlcA unit present in N-sulfo heparosan or the IdoA unit present in CDSNS heparin. If the
polysaccharide contains both GlcA and IdoA units, 2OST prefers IdoA.
Fig. 2. Active site residues of 2OST. (A) Superposition of active sites of 2OST (green) with PAP (cyan) and the cytosolic EST enzyme (gray) with PAP and acceptor
substrate 17-estradiol (E2). The figure displays the position of the acceptor OH of E2 with respect to the proposed catalytic base His-108 in EST. The structurally
equivalent His-142 of 2OST is shown in the 2 conformations displayed in the crystal structure. In contrast, the position of the proposed catalytic base in 3OST-3
(yellow), Glu-184, is shown originating from a different location in the structure, yet the acceptor (data not shown) location is similar to that of the OH of E2
in EST (marked by *). (B) Stereo diagram of the proposed acceptor-binding cleft of a 2OST molecule (green) and the adjacent C-terminal tail of another 2OST
molecule in the trimer (orange). PAPS (purple) is based on a superposition of PAPS from an EST structure with bound PAPS (Protein Data Base ID code 1HY3) onto
the PAP molecule in 2OST. Residues shown lining the cleft were mutated in this work (Table 1).








from elution volumes and molecular mass of protein standards, the
MBP-2OST fusion protein used for crystallization trials eluted with
a calculated molecular mass of 210 kDa, consistent with that of a trimer.
A low-resolution crystallographic dataset collected from crystals
of the catalytic domain of hamster 2OST, lacking a fused MBP
molecule, revealed similar trimer formation. Using the structure of
the chicken 2OST catalytic domain trimer as a search model, we
were able to obtain phases by molecular replacement for data
collected to 3.3 Å on hamster 2OST. The solution revealed 2 trimers
in the asymmetric unit that used protein–protein interactions very
similar to those observed in the chicken 2OST structure. These
results are consistent with a study by Kobayashi et al. (21) that
demonstrated that 2OST isolated from Chinese hamster ovary cells
migrated as an oligomer by gel filtration chromatography (21).
The orientation of the monomers in the trimeric complex posi-
tions the N termini of all 3 molecules on one side of the trimer in
close proximity to one another (Fig. 3B). This orientation is
consistent with a type 2 membrane-bound protein where all 3
molecules would be anchored to the membrane via their N-terminal
transmembrane domains (L12–L27) (22), although this region is
not present in the crystal structure. Positioning of the trimers
separates the active sites from one another, suggesting that the
individual active sites may function independently (Fig. 3 A and B).
One interesting feature of this trimer is the extended C-terminal
tail of 2OST, which forms an antiparallel strand (N345–Y352)
arrangement with the 5th strand (V104–T110) of the central
-sheet of another molecule (Fig. 3 A and B and Fig S2b). This
arrangement situates C-terminal residues Lys-350 and Glu-349 of 1
molecule near the substrate binding site of a second molecule, in a
position to potentially stabilize the active site and participate in
substrate binding (Fig. 3B). It has been reported that C5-epimerase
forms a complex with 2OST (23). However, it is unlikely that
C5-epimerase could occupy one of the trimeric sites of 2OST. In
fact, the purified 2OST from Chinese hamster ovary cells, although
in a trimeric form, did not contain C5-epimerase (21). The pro-
posed in vivo complex perhaps involves a supramolecular structure
between trimeric 2OST and C5-epimerase.
Mutational Analysis of 2OST. Site-directed mutagenesis studies were
performed to identify the roles of specific amino acid residues in the
Fig. 3. Trimeric complex of the catalytic domain of
2OST. (A) View of the 2OST trimer looking down the
3-fold crystallographic axis (monomers are colored
green, blue, and orange). The active sites containing
PAP (khaki) are located on the outer surface of the
trimer. (B) Side view of the trimer based on a 90o
rotation of A, along an axis in the plane of the paper.
The hypothetical positions of the transmembrane N-
terminal helices and the Golgi membrane with respect
to the trimer have been sketched into the figure.















WT 100 100 WT 100 100
R80A 1 2 R188A 100 100
N91A 51 42 R189A 0.3 100
Y94A 90 7 R190A 100 74
D95A 80 32 D208A 76 42
H106A 51 0.4 K213A 100 56
K111A 100 62 K283A 100 100
N112A 97 54 K284A 68 42
H140A 7 0.1 R288A 5 10
H140N 52 14 H330A 100 100
H142A 0.1 0.1 E349A 31 77
H142N 20 3 K350A 22 7
R169A 1 0.3 Y352A 69 43
Y173A 80 50 V332STP 2 0.5
D181A 20 11 L342STP 11 3
Y183A 8 2
*The 2OST mutants were prepared using a modified site-directed mutagenesis protocol from Stratagene. The protein expression level of the mutant proteins
is comparable with the wild-type (WT) protein as determined by the intensity of the Coomassie blue-stained protein band migrated at 70 kDa on SDS/PAGE.
†Theactivityof2OSTwasassayedbyincubatingthepurifiedmutantproteinswitheithercompletelyde-O-sulfatedN-sulfatedheparin(CDSNS-heparin) (-IdoA-GlcNS-)n
or N-sulfo heparosan (-GlcA-GlcNS-)n and 35SPAPS, and the resultant 35S-substrate was quantified by DEAE chromatography, where 100% activity represents the
transfer of 155 pmol of sulfate per g of protein for CDNS-heparin and 65 pmol of sulfate per g of protein for NS-heparosan under the standard assay conditions.
18726  www.pnas.orgcgidoi10.1073pnas.0806975105 Bethea et al.
catalytic function and substrate specificity of 2OST (Table 1).
Amino acid residues that are involved in binding to PAP/PAPS are
not the focus of this work because they have been reported in a
previous publication (20). Instead, amino acid residues lining the
proposed substrate-binding cleft were chosen for mutational anal-
ysis. Mutant enzymes were exposed to 2 polysaccharide substrates
differing in the structure of the disaccharide repeating unit. Com-
pletely desulfated N-sulfated (CDSNS) heparin predominantly has
the repeating disaccharide of -IdoA-GlcNS-, whereas N-sulfo hep-
arosan consists of a repeating structure of -GlcA-GlcNS- (Fig. 1).
Testing the activity of 2OST mutants with these 2 different sub-
strates has permitted us to identify residues that differentiate
between IdoA and GlcA acceptor substrates in the polysaccharide
chain.
Residues involved in catalysis. Based on the crystal structure, 4
residues (Arg-80, His-140, His-142, and Arg-288) are located near
the point of sulfo transfer and thus may be involved in catalysis
and/or acceptor substrate binding. Consistent with previous alanine
scanning mutagenesis experiments, our results demonstrate that
these residues are important for activity (20). In the crystal struc-
ture, Arg-80 and Arg-288 are located near the proposed position of
the sulfo moiety on the PAPS molecule and therefore may be
involved in stabilization of the transition state and/or substrate
binding (Fig. 2B). The R80A and R288A mutants display 10% or
less activity toward polysaccharide substrates (Table 1).
Previously, it was demonstrated that the mutations H140A and
H142A greatly reduced the activity of 2OST and that the double
mutant H140A/H142A resulted in complete loss of activity (20).
The crystal structure reveals that His-142 is in position potentially
to serve as a catalytic base facilitating the deprotonation of the
acceptor substrate, whereas His-140 is located more distal to the
point of sulfo transfer and is in position to form a hydrogen bond
with Arg-80. The H142A mutant of chicken 2OST had no detect-
able activity with the 2 substrates, supporting its essential role as a
catalytic base, whereas 2OST H140A retains 7% of wild-type
activity against IdoA containing substrate (CDSNS heparin). To
probe the functions of His-140 and His-142 further, mutants H140N
and H142N were prepared. The H140N mutant maintained 52%
activity against IdoA-containing substrate and 14% against GlcA-
containing substrate (N-sulfo heparosan). Based on the crystal
structure, it appears that the asparagine substitution could still form
a hydrogen bond with Arg-80. Thus, the major role of His-140 may
be to position Arg-80 properly. Surprisingly, the H142N mutant
maintains 20% and 3% of wild-type activity against IdoA- and
GlcA-containing substrates, respectively. In contrast, the equivalent
mutation of His-107 of human EST to asparagine abolished the
sulfotransferase activity (19). One possible explanation for the
residual activity of the H142N mutant vs. H142A is that a water
molecule could occupy the location of the N2 atom of the histidine
side chain, stabilized by interactions with Asn-142, and substitute as
a weak proton acceptor in the absence of the histidine side chain.
An additional possibility is that the reaction for 2OST is more
dissociative in nature, compared with EST, with greater emphasis
on bond breaking and stabilization of the leaving group rather than
deprotonation of the nucleophile, decreasing the need for a strong base.
Residues involved in trimer formation. Several residues along the
C-terminal tail were subjected to mutational analysis, including
His-330, Glu-349, Lys-350, and Tyr-352 (Fig. 2B). The only residue
showing a loss of activity 70% was the Lys-350 mutant (Table 1).
The side chain of this residue is extended into the active site of the
adjacent molecule, suggesting that it could play a minor role in
substrate binding. Although no single point mutation from this
region caused a severe decrease in activity, introduction of a
premature stop codon after either Val-332 or Leu-342 resulted in
a drastic loss in activity toward both substrates. These data suggest
that deletion of residues along the C terminus eliminates the
intermolecular interactions between the protein backbone atoms,
disrupting the adjacent active site and potentially destabilization of
the protein and/or the protein trimeric complex. To determine
whether the truncation mutant disrupted the trimeric complex, the
mutant protein was analyzed by gel filtration chromatography. The
chromatogram for the wild-type MBP-2OST revealed 3 distinct
peaks (Fig. 4A) representing aggregated MBP-2OST (peak 1,
fractions 3–9) in the void volume, trimeric MBP-2OST (peak 2,
fractions 12–16) (sample used for crystallization trials), and MBP
(peak 3, fractions 23–28), respectively. Of these peaks, the only one
containing sulfotransferase activity was that consistent with the
trimer.
The mutant (2OST V332STP) revealed a starkly different elu-
tion profile from the wild-type MBP-2OST construct. The aggre-
gated protein elutes with intensity and position similar to the
normal wild-type MBP-2OST; however, there is a substantial
decrease in the intensity of the trimeric 2OST peak and the
appearance of an additional peak before MBP between fractions 19
and 23 (Fig. 4B). This peak corresponds to a molecular mass of 70
kDa and represents monomeric MBP-2OST (Fig. 4C). Sulfotrans-
Fig. 4. Comparison of the oligomeric state of 2OST wild-type with 2OST
V332STP. Approximately 7 mg of amylose–agarose column-purified wild-type or
premature stop codon mutant (V332STP) 2OST was analyzed by gel permeation
chromatography. The sulfotransferase activity was also determined by using
CDSNS heparin as a substrate. The UV absorbance and sulfotransferase activity
are plotted against fraction number for wild-type (A) and mutant (B) 2OST. The
molecular mass standards resolved under the same experimental conditions are
indicated by arrows. One unit is equivalent to 1 pmol of sulfate transferred to the
substrate under standard reaction conditions. (C) Fractions that were analyzed by
SDS/PAGE for both the 2OST wild-type and 2OST V332STP. The fractions analyzed
are labeled with a number above each lane of the SDS gel. SDS/PAGE analysis of
these fractions from gel permeation chromatography confirmed the presence of
2OST within all fractions from 5 to 23. Both 2OST WT and 2OSTV332STP are MBP
fusion proteins.








ferase activity was detected predominantly within the trimeric peak
and the monomeric 2OST peak, but at a lower level. The activity for
the mutant trimer is substantially lower than for the wild-type
protein, suggesting that the extended C-terminal tail influences
trimer formation and is crucial for the activity.
Residues involved in substrate binding and specificity. Residues Tyr-94,
His-106, Arg-169, Asp-181, Tyr-183, Arg-189, and Lys-350 are
located in the substrate-binding cleft but distal to the catalytic core,
implicating them in acceptor substrate binding (Fig. 2B). Mutations
of these residues showed a noticeable effect on enzymatic activity
(Table 1). Of these mutations, Y183A and R169A resulted in a
substantial loss of activity toward both CDSNS heparin and N-sulfo
heparosan. Tyr-183 is located toward the predicted nonreducing
end of the binding pocket based on comparisons with the crystal
structure of 3OST-3 (16). The side chain of Tyr-183 extends into the
solvent, suggesting that it does not play a structural role, but rather
may play a significant role in substrate binding. The side chain of
Arg-169 is located on the reducing end of the binding pocket. Most
of this side chain is buried with the guanidinium moiety on the
surface of the binding pocket. Arg-169 is conserved in NST and the
3OST isoforms as well. In the 3OST-3 structure with a tetrasac-
charide bound, this residue (Arg-248) does not directly interact with
the substrate. The main role of Arg-169 may be to stabilize the PSB
loop because the guanidinium moiety is within hydrogen-bonding
distance to the backbone carbonyl oxygen of Pro-82 in this loop.
Also lining the pocket, but largely buried, is the side chain of
Asp-181. This residue is in position to form hydrogen bonds with
Arg-189 (2.8 Å) and/or Arg-288 (2.9 Å). Such interactions suggest
that Asp-181 may help position Arg-288 and Arg-189 for substrate
binding and/or catalysis. As with Arg-288, replacing Asp-181 with
alanine resulted in substantial loss of the sulfotransferase activity
toward both CDSNS heparin and N-sulfo heparosan (Table 1).
Although wild-type 2OST sulfates both GlcA and IdoA in HS
substrates, the mutants H106A, Y94A, and R189A showed pref-
erence for one substrate over the other. Both Y94A and H106A
mutants sulfated CDSNS heparin, the IdoA-containing substrate,
but lost activity with N-sulfo heparosan, the GlcA-containing
substrate, displaying 10-fold and 100-fold differences in percentage
activity, respectively. These results suggest that Tyr-94 and His-106
allow recognition of the GlcA-containing substrate. Thus, replacing
either residue with alanine resulted in a substantial preference for
the polysaccharide substrate containing IdoA.
Most impressive was the selective preference of R189A for the
GlcA-containing substrate over IdoA. The mutant R189A retained
full activity with the GlcA-containing substrate but showed virtually
no activity with the IdoA-containing substrate. This observation
suggested that residue Arg-189 is likely important for recognition of
IdoA-containing substrate, and replacing the arginine residue with
an alanine does not allow the enzyme to exhibit substrate flexibility.
To examine the role of Arg-189 in substrate recognition further,
we reconstituted the biosynthesis of IdoA2S in vitro. The N-sulfo
heparosan, similar to the unepimerized polysaccharide substrate
Fig. 5. Reverse-phase ion pairing-HPLC chromatograms of the disaccharide analysis of 2OST wild-type and 2OST R189A-modified polysaccharides. (A)
Chromatogram of nitrous acid degraded 2-O-[35S]sulfated N-sulfo heparosan using 2OST wild-type enzyme in the presence (blue line) or absence (red line) of
C5-epimerase modification. (B) Chromatogram of nitrous acid degraded 2-O-[35S]sulfated N-sulfo heparosan using 2OST R189A enzyme with (blue line) or
without (red line) C5-epimerase modification. (C) Reactions involved in preparing 2OST-modified polysaccharide with or without C5-epimerase and degradation
by nitrous acid. AnMan represents 2,5-anhydromannitol.
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(precursor of HS) (24), was incubated with wild-type 2OST and
2OST R189A in the presence or absence of C5-epimerase, where
C5-epimerase converts part of the GlcA to IdoA (as illustrated in
Fig. 5C). We characterized the resultant polysaccharides by disac-
charide analysis of the products (Fig. 5 A and B). As expected, the
product modified by wild-type 2OST predominantly contains
GlcA2S in the absence of C5-epimerase (Fig. 5A, red line) or
IdoA2S in the presence of C5-epimerase (Fig. 5A, blue line) (8). In
contrast, the products modified by 2OST R189A contain only
GlcA2S regardless of the absence or presence of C5-epimerase
(Fig. 5B), suggesting that the mutant protein does not recognize
IdoA as an acceptor unit in the polysaccharide substrate.
The roles of Tyr-94, His-106, and Arg-189 in directing the
substrate specificity are currently unknown because the structure of
a ternary complex containing an appropriate oligosaccharide sub-
strate is not available. However, based on gel filtration chromatog-
raphy analysis, the Y94A, H106A, and R189A mutants migrate as
a trimer similar to wild-type enzyme (Fig. S4). Thus, these muta-
tions do not lead to large-scale structural changes that disrupt the
active trimer, supporting a local effect on substrate recognition as
the cause for differences in substrate specificity.
Conclusions
Unlike previously characterized HS sulfotransferases, 2OST is
present in a trimeric form that appears to be essential for enzymatic
activity. Based on the structure, we have identified several amino
acid residues that are involved in polysaccharide substrate binding.
Mutation of these amino acid residues alters the spectrum of
substrate specificity of 2OST. A mutant protein with altered
substrate specificity offers the possibility to synthesize selected HS
products that cannot be achieved by wild-type 2OST. For example,
2OST R189A selectively sulfates the GlcA unit in the presence of
IdoA, producing GlcA2S- but not IdoA2S-containing HS polysac-
charides. One potential application of this mutant or perhaps
another similarly engineered sulfotransferase would be to synthe-
size therapeutic heparin with reduced side effects. Heparin-induced
thrombocytopenia is a major side effect of therapeutic heparin,
caused in part by heparin-binding platelet factor 4. It is known that
the IdoA2S unit, the product of wild-type 2OST modification, is
involved in heparin binding to platelet factor 4 (25). Using the 2OST
R189A mutant to synthesize heparin, we will be able to replace the
IdoA2S unit by GlcA2S, hopefully reducing the side effect. An-
other potential application of engineered 2OST will be to allow us
to produce HS and heparin with highly enriched GlcA2S units for
probing the biological function in glycomics studies (26).
Methods
Cloning, Expression, and Purification of Chicken 2OST. The MBP-2OST fusion
protein was created by using a modified pMAL-c2x vector (New England Biolabs).
The amino acid sequence of MBP was truncated at Asn-367 and contained the
mutation E359A (27). The linker region encodes 3 alanine residues (A368–A370)
and contained an NotI site for cloning. The catalytic domain of chicken 2OST
(D69–N356) was cloned into the vector by using the NotI and BamHI sites. The
MBP-2OST was expressed in Origami B(DE3) cells (Novagen). Cells were grown on
a shaker at 37 °C in LB medium and induced with isopropyl--D-thiogalactopyr-
anoside. Cells were allowed to shake overnight at 18 °C. Cells were pelleted,
resuspened in 25 mM Tris (pH 7.5), 500 mM NaCl, and 1 mM DTT, and then lysed
by sonication. MBP-2OST was bound to amylose resin (New England Biolabs),
eluted with maltose, then loaded onto a HR16/60 Superdex 200 (Amersham)
column preequilibrated in the sonication buffer containing 40 mM maltose. The
purified protein was then dialyzed overnight against 25 mM Tris (pH 7.5), 75 mM
NaCl, 5 mM maltose, and 1 mM DTT. PAP was added to 1 mM. The sample was
concentrated to 19 mg/mL, followed by the addition of more PAP for a final
concentration of 4 mM.
In addition, a C-terminal (His)6-tagged 2OST expression construct was pre-
pared by cloning the catalytic domain of hamster 2OST (R63–N356) into the
pET-21b vector (Novagen) by using NdeI and HindIII sites. The procedures for the
expression and purification of hamster 2OST are described in ref. 20.
Determination of the Substrate Specificity of 2OST R189A. Because N-sulfo
heparosan contains no IdoA unit, it was incubated with recombinant C5-
epimerase to synthesize the IdoA unit followed by 2OST modification. To this
end, N-sulfo heparosan (9 g) was incubated with C5-epimerase (7 g) in a buffer
containing 50 mM Mes (pH 7.0), 1% Triton X-100, and 2 mM CaCl2 for 1 h at 37 °C.
To this reaction, 10 g of 2OST R189A or 2OST WT and 1.5  106 cpm of [35S]PAPS
were added. The 2-O-[35S]sulfated polysaccharide was purified by a DEAE col-
umn. The position of the 2-O-[35S]sulfo group in the polysaccharide was deter-
mined by disaccharide analysis. Briefly, the resultant 35S-labeled polysaccharide
was degraded to disaccharides with nitrous acid at pH 1.5 followed by reduction
with sodium borohydride. The disaccharide products were then analyzed by
reverse-phase ion-pairing HPLC. The identities of the resultant 35S-labeled disac-
charidesweredeterminedbycoelutionwithappropriatedisaccharidestandards(28).
Additional experimental procedures are presented under SI Text.
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